Investor Presentaiton

Strong Commercialization to Enhance Leadership in China PD-1 Market and to Capture Huge Potentials in Global Market Robust Product Revenue Growth¹ RMB mn 2,500 RMB 2,368mn 2,000 1,500 Y-o-Y -Y growth: 133.0% Y-o-Y growth: 101.4% RMB 1,855mn First-mover Advantage Comprehensive Development Strategy Maintain strong leadership position in China market RMB 1,016mn • RMB 921mn Strong revenue growth and leading market share 1,000 500 NMPA approval in Dec 2018 Out-license Partnership with Eli Lilly Backbone role for oncology TA Best positioned to explore huge potential in global markets • • First PD-1 included in NRDL in 2019 New indication approvals on • • Extensive network and experienced marketing and sales team (~2,000 ppl) . Manufacturing capacity: 24,000L in operation and additional 36,000L in construction • • • large cancers: 1L nsq NSCLC (approved in Feb 2021), 1L sq NSCLC and 1L HCC (approved in June 2021), 2L sq NSCLC 1L ESCC and 1L GC met primary endpoints TYVYT as one of a few PD-1 inhibitors that has shown to be efficacious in the 1L treatment of five major types of cancer Combo/bispecific with internal • First marketed China PD-1 out-licensed to global MNC pharmaceutical company 2021 May: BLA for sintilimab for 1L nsqNSCLC accepted by the U.S. FDA in May 2021 • Global PD-1 market size and valuation multiple times larger than that in China market H 2018 2019 2020 2020 1H 2021 1H pipeline (CTLA-4, TIGIT, FGFR, LAG-3, VEGF, etc.) Innovent is confident to maintain TYVYTⓇ as the leading PD-1 brand in China market and is best positioned to capture the much larger potential in global markets. Note:1) Product revenue included all approved products' sales revenue Innovent Confidential Copyright©2021 Innovent Biologics 7

View entire presentation